HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research P...(elationship between protein expression p...),Health

Date:9/4/2007

elationship between protein expression patterns and disease gains an expanding role in new drug and diagnostic development and in the way physicians treat patients and individualize therapeutic regimens, we continue to advance our goal of replacing conventional immunohistochemistry with AQUA(R) analysis, a more precise and consistent tool that is enabling pathologists and clinicians to integrate data from predictive biomarker studies confidently into research, diagnosis, and patient treatment," said Rana K. Gupta, CEO of HistoRx. "We are pleased to have reached this agreement with such a renowned organization as The Radiation Therapy Oncology Group and to have its endorsement of the AQUA(R) technology's predictive power and potential for developing companion diagnostic and prognostic assays."

About HistoRx (http://www.historx.com)

HistoRx is a systems pathology company developing and commercializing quantitative biomarker analysis technology that provides exceptional measurement and localization of proteins in their natural context within tissue. The pioneering HistoRx proprietary AQUA(R) (Automated Quantitative Analysis) technology is the first platform capable of measuring biomarker concentration with subcellular resolution to generate more precise, efficient answers about the safety and effectiveness of new therapeutics in development and to enable development of companion diagnostic tests for targeted therapies. HistoRx services are used by pharmaceutical and biotechnology companies throughout the drug discovery, preclinical study, and clinical development continuum. HistoRx has two lines of diagnostic products in development: HistoRx companion diagnostic products are linked to partners' drug candidates in development to predict prognostic outcome; and HistoRx is independently developing AQUA(R)-based diagnostics for the clinical diagnosis, prognosis, and treatment management of complex diseases.

'/>"/>

SOURCE HistoRx, Inc. Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Aeolus Pharmaceuticals AEOL 10113 May Play an Important Role Regulating the Oxidative Damage Induced by Ionizing Radiation
2. Aeolus Pharmaceuticals AEOL 10113 Demonstrates Potential as a Protector of Healthy Normal Cells from Cancer Radiation Therapy
3. Viventia biotech reports synergystic effect of its Proxinium antibody in combinaton with chemotherapy and radiation
4. Cleveland BioLabs Protectan CBLB502 Demonstrates Strong Survival Benefits as Mitigator Against Radiation-Induced Damage in Study
5. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
6. Hollis-Eden Announces Cancellation of Acute Radiation Syndrome RFP by Department of Health and Human Services
7. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
8. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
9. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
10. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
11. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy